证券代码：600436 证券简称：片仔癀 公告编号：2023-031 漳州片仔癀药业股份有限公司 关于增加签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）于 2023 年 4 月 13 日召开第七届董事会第十次会议，并于 2023 年 6 月 15 日召 开 2022 年年度股东大会审议通过了《公司关于聘任会计师事务所及 确定其报酬事项的议案》，同意续聘华兴会计师事务所（特殊普通合 伙）（以下简称"华兴所"）为公司 2023 年度财务报告审计和内部控 制审计机构。具体内容详见公司于 2023 年 4 月 15 日在上海证券交 易所网站披露的《公司关于续聘会计师事务所的公告》（公告编号： 2023-006）。 近日，公司收到华兴所出具的《关于增加一名签字注册会计师 的告知函》。现将有关情况公告如下： 一、本次增加签字注册会计师的基本情况 华兴所作为公司聘请的 2023 年度财务报告审计和内部控制审计 机构，原委派童益恭先生为项目合伙人及签字注册会计师、林隽先 生 ...

重要内容提示： 漳州片仔癀药业股份有限公司（以下简称"公司"）取得 《PZH2108 片 I 期临床研究报告》对公司本年度的财务状况和经营业 绩无重大影响。 由于药品研发的特殊性，从批准临床、临床试验、申报生产到 最终取得药品注册证书，具有周期长、环节多、风险大、投入高的特 点，容易受到政策、技术、市场、竞品研发情况等多方面因素的影响， 存在诸多不确定性风险。 公司将密切关注该药物研发事项的后续进展情况，及时履行信 息披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 近日，公司治疗癌性疼痛创新药 PZH2108 片已完成Ⅰ期临床试验 并取得《PZH2108 片Ⅰ期临床研究报告》，研究结果显示 PZH2108 片 各研究剂量组在中国健康受试者中安全性及耐受性良好。现将相关内 容公告如下： 证券代码：600436 证券简称：片仔癀 公告编号：2023-028 漳州片仔癀药业股份有限公司 关于取得《PZH2108 片 I 期临床研究报告》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册分类：化学药品 1 类 临床受理 ...

单位：万元人民币 姓名 2022 年度从本公司获得的税前报酬情况 （单位：万元） 在股东 单位或 其他关 联方领 取薪酬 （是/ 否） 应付薪酬 社会保险 金、企业年 金、补充医 疗保险及住 房公积金的 单位缴存部 分 其他货币 性收入 （注明具 体项目并 分列） 合计 黄进明 60.52 13.97 0.00 74.49 否 陈纪鹏 53.26 13.32 0.00 66.58 否 杨海鹏 53.26 13.32 0.00 66.58 否 洪绯 53.26 13.32 0.00 66.58 否 陈鸿辉 34.87 11.24 0.00 46.11 否 备注： 证券代码：600436 证券简称：片仔癀 公告编号：2023-030 漳州片仔癀药业股份有限公司 关于董事、监事和高级管理人员薪酬的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 4 月 15 日，漳州片仔癀药业股份有限公司（以下简称 "公司"）在《公司 2022 年度报告》披露了公司董事、监事、高级 管理人员在报告期内从公司获得的税前报酬总额。 ...

漳州片仔癀药业股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善公司法人治理结构，促进公司规范运作，强化对董事会及经理层 的约束和监督，更好地维护漳州片仔癀药业股份有限公司（下称"公司"或"本公司"）及 中小股东利益，根据《中华人民共和国证券法》和中国证监会《上市公司独立董事管理办法》 《上市公司治理准则》等相关规定，制定本制度。 第二章 一般规定 第二条 独立董事是指不在本公司担任除董事、董事会专门委员会委员外的任何其他职 务，并与本公司及本公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可 能影响其进行独立客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，依法履行董事义务。独立董 事应当按照国家相关法律法规和《公司章程》的要求，认真履行职责，在董事会中发挥参与 决策、监督制衡、专业咨询作用，维护公司和全体股东的利益，尤其要关注中小股东的合法 权益不受损害。公司应当保障独立董事依法履职。 公司股东间或者董事间发生冲突、对公司经营管理造成重大影响的，独立董事应当主动 履行职责，维护公司整体利益。 第四条 独立董事应当独立履行职责，不受本公司及主要股东、实际 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥2,554,601,056.83, representing a year-on-year increase of 14.88%[2] - Net profit attributable to shareholders for the same period was ¥863,811,361.31, reflecting a growth of 17.16% compared to the previous year[2] - The basic earnings per share (EPS) for Q3 2023 was ¥1.43, an increase of 17.35% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached CNY 7,599,876,766.77, an increase of 14.85% compared to CNY 6,615,770,012.53 in the same period of 2022[14] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was CNY 2,404,648,414.60, up 17.09% from CNY 2,052,489,398.59 in the previous year[15] - Total comprehensive income for the first three quarters of 2023 was CNY 2,489,529,240.25, compared to CNY 1,951,749,440.46 in the previous year, indicating an increase of 27.43%[15] - Earnings per share for the first three quarters of 2023 were CNY 3.99, compared to CNY 3.40 in the same period of 2022, reflecting an increase of 17.32%[15] - Net profit for the first three quarters of 2023 was CNY 2,221,602,003.20, up from CNY 2,028,350,590.65 in the previous year, reflecting a growth of 9.5%[25] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥16,095,502,214.16, marking a 10.21% increase from the end of the previous year[2] - Current assets totaled CNY 14,133,327,275.50, up from CNY 12,704,827,396.23, indicating a growth of about 11.2% year-over-year[12] - Total liabilities decreased to CNY 2,536,265,935.87 from CNY 2,779,905,281.31, showing a reduction of about 8.8%[13] - Total assets as of September 30, 2023, amounted to CNY 12,802,385,635.14, compared to CNY 11,429,168,891.70 at the end of 2022, indicating a year-to-date increase of 12.0%[22] - Current assets totaled CNY 10,388,213,575.16, up from CNY 8,929,960,401.55 in 2022, representing a growth of 16.3%[22] - The total liabilities decreased to CNY 648,494,918.43 from CNY 674,768,721.93, showing a reduction of 3.9%[22] Cash Flow - The net cash flow from operating activities showed a significant decline of 61.44%, totaling ¥2,379,535,115.02[2] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 2,379,535,115.02, a decrease of 61.49% from CNY 6,170,796,213.66 in the previous year[17] - The net cash flow from investment activities was -¥816,505,525.85, compared to -¥5,345,460,200.81 in the same period of 2022, indicating a reduced outflow[26] - Total cash inflow from operating activities was ¥3,886,560,257.62, down from ¥7,443,909,855.55 in the previous year[26] - The ending balance of cash and cash equivalents was ¥1,619,784,597.84, up from ¥1,276,342,187.92 in the previous year[27] Shareholder Information - Shareholders' equity attributable to the parent company reached ¥13,007,315,771.02, up 14.80% compared to the previous year[2] - The top shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., holds 51.30% of the shares, with 309,522,643 shares[8] - The company's equity attributable to shareholders rose to CNY 13,007,315,771.02, up from CNY 11,329,967,292.12, marking an increase of approximately 14.8%[13] - The company’s total equity increased to CNY 12,153,890,716.71 from CNY 10,754,400,169.77, representing a growth of 13.0%[22] Research and Development - Research and development expenses increased to CNY 180,199,926.54, compared to CNY 143,261,715.23 in the same period last year, reflecting a growth of 25.76%[14] - The company reported a significant increase in research and development expenses, totaling CNY 153,891,377.05 for the first three quarters of 2023, compared to CNY 123,899,232.47 in the same period of 2022, reflecting a rise of 24.2%[24] Operational Developments - The company has not reported any new product launches or technological developments in this quarter[1] - There are no significant mergers or acquisitions reported during this period[1] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23]

根据《中华人民共和国证券法（2019 年修订）》《上海证券交易所股 票上市规则（2023 年修订）》和《上海证券交易所上市公司自律监管指南 第 1 号——公告格式》（2023 年修订）》等相关法律法规，作为漳州片仔 癀药业股份有限公司的董事、监事和高级管理人员，我们在全面了解和审 核《公司 2023 年第三季度报告》后，发表意见如下： 漳州片仔癀药业股份有限公司 董事、监事和高级管理人员 漳州片仔癀药业股份有限公司董事、监事和高级管理人员 关于公司 2023 年第三季度报告的确认意见 2023 年 10 月 16 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2023 年第 三季度报告的编制符合法律、行政法规、《漳州片仔癀药业股 份有限公司章程》及公司内部管理制度的各项规定，《公司 2023 年第三季度报告》公允、真实、全面地反映了公司 2023 年第三 季度的财务状况和经营成果。 2、 公司第七届董事会第十五次会议、第七届监事会第十次会议审 议通过《公司 2023 年第三季度报告》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2023 年第三季 度报告》所披露的信息真实、准确、完整 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 5,045,275,709.94, representing a 14.08% increase compared to CNY 4,422,632,056.64 in the same period last year[12]. - Net profit attributable to shareholders for the first half of 2023 was CNY 1,540,837,053.29, up 17.23% from CNY 1,314,364,302.27 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was CNY 1,577,264,060.05, reflecting a 19.80% increase from CNY 1,316,611,524.12 in the same period last year[12]. - Basic earnings per share for the first half of 2023 were CNY 2.55, up 16.97% from CNY 2.18 in the same period last year[13]. - The company reported a total profit of ¥1,861,157,111.49, compared to ¥1,597,624,302.34 in the same period last year, marking a growth of 16.4%[100]. - The total comprehensive income for the first half of 2023 was ¥1,598,392,363.53, compared to ¥1,267,092,706.30 in the previous year, reflecting a growth of 26.1%[102]. Cash Flow and Financial Position - The company's net cash flow from operating activities decreased by 74.49%, amounting to CNY 1,368,609,738.45 compared to CNY 5,364,583,037.99 in the previous year[12]. - The company reported a significant increase in non-operating income by 157.00% to ¥1,829,433.43, driven by government subsidies and other gains[34]. - The company experienced a 1,753.88% decrease in net cash flow from financing activities, primarily due to reduced cash received from borrowings[36]. - The total cash inflow from operating activities was ¥2,280,492,801.51, down from ¥6,013,353,115.18 year-on-year[109]. - The company reported a net cash outflow from investment activities of ¥494,735,901.98, compared to a larger outflow of ¥5,212,896,238.65 in the previous year[109]. Assets and Liabilities - As of June 30, 2023, the net assets attributable to shareholders were CNY 12,129,601,206.27, a 7.06% increase from CNY 11,329,967,292.12 at the end of the previous year[12]. - Total assets increased by 8.92% to CNY 15,907,148,751.88 from CNY 14,603,844,518.45 at the end of the previous year[12]. - The company's total liabilities reached CNY 3,239,112,379.36, compared to CNY 2,779,905,281.31 at the end of 2022, marking an increase of around 16.5%[96]. - The company's total current liabilities amounted to CNY 2,970,582,277.19, up from CNY 2,510,181,610.40, indicating an increase of about 18.3%[96]. Industry Context - The pharmaceutical manufacturing industry saw a revenue decline of 2.9% year-on-year, totaling 1,249.6 billion RMB in the first half of 2023[17]. - The total profit for the pharmaceutical manufacturing industry decreased by 17.1% year-on-year, amounting to 179.45 billion RMB[17]. Product Development and Innovation - The company has not disclosed any new product developments or market expansion strategies in this report[14]. - The company is advancing over 10 clinical research projects related to its core product, Pian Zai Huang, focusing on liver disease, tumors, and antiviral treatments[24]. - Three Class 1 chemical new drugs and three Class 1.1 traditional Chinese medicine new drugs are currently in clinical research stages, indicating a robust pipeline for future product offerings[24]. - The company aims to strengthen its core position in the health sector by focusing on the development of its Pian Zai Huang series of products, cosmetics, and health foods[22]. Market Presence and Brand Value - The company has established strategic partnerships with over 10,000 retail stores through collaborations with major chain pharmacies, enhancing its market presence across key regions such as Fujian, Guangdong, and Beijing[22]. - The brand value of the company's "Pian Zai Huang" reached 40.937 billion CNY, ranking first in the "Hurun Brand List for Medical Health Brands" for two consecutive years (2021-2022) and second in the "Chinese Time-honored Brand" category[21]. Environmental and Social Responsibility - The company emphasizes environmental protection and compliance with new regulations, implementing measures to reduce environmental risks and enhance sustainability practices[59]. - The company actively supports the "Healthy China" national strategy and has established a precision poverty alleviation demonstration base in collaboration with Taibai County and Ning Shan County, providing technical support and funding to local farmers[81]. - During the reporting period, the company donated a total of 690,000 RMB to various charitable causes, including 200,000 RMB for children with severe illnesses and 400,000 RMB for educational support[81]. Governance and Compliance - The company held two shareholder meetings in 2023, with all proposed resolutions approved, indicating strong governance[62]. - The financial statements were approved by the board on August 17, 2023, ensuring compliance with accounting standards[119]. - The company has undergone changes in its board of directors, with new independent directors elected to strengthen governance[64].

漳州片仔癀药业股份有限公司 漳州片仔癀药业股份有限公司董事、监事和高级管理人员 关于公司 2023 年半年度报告的确认意见 根据《中华人民共和国证券法（2019 年修订）》《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》（2021 年修订）》和《上海证券交易所股票上市规则（2023 年修订）》等相关规 定和要求，作为漳州片仔癀药业股份有限公司的董事、监事和高级管理人 员，我们在全面了解和审核《公司 2023 年半年度报告》后，发表意见如 下： 董事、监事和高级管理人员 2023 年 8 月 17 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2023 年半 年度报告的编制符合法律、行政法规、《漳州片仔癀药业股份 有限公司章程》及公司内部管理制度的各项规定，2023 年半年 度报告公允、真实、全面地反映了公司 2023 年半年度报告的财 务状况和经营成果。 2、 公司第七届董事会第十四次会议、第七届监事会第九次会议审 议通过《公司 2023 年半年度报告及摘要》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2023 年半年度 报告及摘要》所披露的信息真 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-026 审计委员会：贾建军（主任委员）、杜守颖、赖文宁 提名委员会：李广培（主任委员）、林纬奇、范志鹏、杜守颖 1 / 2 漳州片仔癀药业股份有限公司 关于调整董事会专门委员会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）原独立董事 贾建军先生、李广培先生于2017年8月起，连任公司独立董事时间达 到六年，任期届满。上述两位独立董事向公司董事会提请辞去独立董 事及董事会下属专门委员会相关职务。公司于2023年5月22日召开第 七届董事会第十一次会议，审议通过《公司关于选举独立董事的议 案》，会议增补陈蕾女士、张磊先生为公司第七届董事会独立董事候 选人，并经2023年6月15日的2022年年度股东大会审议通过。 公司原董事长林纬奇先生因工作调整，向董事会辞去公司董事、 董事长及董事会下属专门委员会委员等职务。公司于2023年7月24日 召开第七届董事会第十二次会议，审议通过《公司关于增补董事的议 案》，会议增补林 ...

表决结果：8 票同意，0 票反对，0 票弃权。 证券代码：600436 证券简称：片仔癀 公告编号：2023-025 漳州片仔癀药业股份有限公司 第七届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第十三次会议于 2023 年 8 月 9 日（星期三）下午 16:30 以现场与 通讯相结合方式在芗江酒店一楼芗江 A 厅会议室召开。会议通知和议 案以专人送达、电子邮件方式发出。本次会议应参加表决董事 8 人， 实际表决董事 8 人。经全体董事同意，本次会议豁免通知时限要求。 经半数以上董事推举，会议由董事林志辉先生主持。本次会议召开符 合《公司法》与《漳州片仔癀药业股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，合法、有效。到会董事以通讯方式表决， 审议以下议案： 一、 审议通过《公司关于选举董事长的议案》； 特此公告。 漳州片仔癀药业股份有限公司 董 事 会 为规范公司运作，完善法人治理结构，根据《公司章程》等相关 规定，董事 ...